SCLX Dec 2024 3.000 call
- GlobeNewswire
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year.Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year.Total product net sales for the quarter ended June 2024 grew in the range of 30% to 44%, compared to the same period last year. PALO ALTO,
- GlobeNewswire
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and
- GlobeNewswire
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of Pain, and features original research on the nature, mechanisms and treatment of pain.This Phase 3 study met primary and important key secondary endpoints, with SP-102 (SEMDEXA™) treatment, decreasing pain intensity for over a month in sciatica patients and resulting in statistically signi
